share_log

China Zhenhua (Group) Science & Technology Co., Ltd Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

China Zhenhua (Group) Science & Technology Co., Ltd Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

振華科技集團有限公司未達到分析師的預期收益:這是分析師現在的預測
Simply Wall St ·  08/27 19:14

As you might know, China Zhenhua (Group) Science & Technology Co., Ltd (SZSE:000733) last week released its latest second-quarter, and things did not turn out so great for shareholders. Unfortunately, China Zhenhua (Group) Science & Technology delivered a serious earnings miss. Revenues of CN¥1.4b were 18% below expectations, and statutory earnings per share of CN¥0.58 missed estimates by 23%. This is an important time for investors, as they can track a company's performance in its report, look at what experts are forecasting for next year, and see if there has been any change to expectations for the business. So we gathered the latest post-earnings forecasts to see what estimates suggest is in store for next year.

你可能知道,中國振華(集團)科技股份有限公司(SZSE: 000733)上週發佈了最新的第二季度,但對股東來說情況並不那麼好。不幸的是,中國振華(集團)科技嚴重虧損。14元人民幣的收入比預期低18%,0.58元人民幣的法定每股收益比預期低23%。對於投資者來說,這是一個重要時刻,因爲他們可以在報告中追蹤公司的業績,看看專家對明年的預測,看看對該業務的預期是否有任何變化。因此,我們收集了最新的業績後預測,以了解估計對明年的預測。

1724800495148
SZSE:000733 Earnings and Revenue Growth August 27th 2024
SZSE: 000733 收益和收入增長 2024 年 8 月 27 日

Taking into account the latest results, the current consensus, from the four analysts covering China Zhenhua (Group) Science & Technology, is for revenues of CN¥5.01b in 2024. This implies a chunky 15% reduction in China Zhenhua (Group) Science & Technology's revenue over the past 12 months. Statutory earnings per share are forecast to descend 11% to CN¥2.52 in the same period. Yet prior to the latest earnings, the analysts had been anticipated revenues of CN¥7.07b and earnings per share (EPS) of CN¥4.42 in 2024. Indeed, we can see that the analysts are a lot more bearish about China Zhenhua (Group) Science & Technology's prospects following the latest results, administering a pretty serious reduction to revenue estimates and slashing their EPS estimates to boot.

考慮到最新業績,負責中國振華(集團)科學與技術的四位分析師目前的共識是,2024年的收入爲50.1元人民幣。這意味着中國振華(集團)科技在過去12個月中的收入大幅減少了15%。預計同期法定每股收益將下降11%,至2.52元人民幣。然而,在最新業績公佈之前,分析師曾預計2024年的收入爲70.7元人民幣,每股收益(EPS)爲4.42元人民幣。事實上,我們可以看到,分析師對中國振華(集團)科技在最新業績公佈後的前景更加悲觀,他們大幅下調了收入預期,並下調了每股收益預期。

It'll come as no surprise then, to learn that the analysts have cut their price target 37% to CN¥45.44.

因此,得知分析師已將目標股價下調37%至45.44元人民幣也就不足爲奇了。

These estimates are interesting, but it can be useful to paint some more broad strokes when seeing how forecasts compare, both to the China Zhenhua (Group) Science & Technology's past performance and to peers in the same industry. We would highlight that revenue is expected to reverse, with a forecast 28% annualised decline to the end of 2024. That is a notable change from historical growth of 16% over the last five years. Compare this with our data, which suggests that other companies in the same industry are, in aggregate, expected to see their revenue grow 18% per year. So although its revenues are forecast to shrink, this cloud does not come with a silver lining - China Zhenhua (Group) Science & Technology is expected to lag the wider industry.

這些估計很有趣,但是在查看預測與中國振華(集團)科學與技術過去的表現以及與同一行業的同行進行比較時,可以更粗略地描繪一些線索。我們要強調的是,收入預計將逆轉,預計到2024年底,年化下降28%。與過去五年16%的歷史增長相比,這是一個顯著的變化。相比之下,我們的數據表明,總體而言,同一行業的其他公司的收入預計每年將增長18%。因此,儘管預計其收入將萎縮,但這種陰雲並沒有帶來一線希望——預計中國振華(集團)科技將落後於整個行業。

The Bottom Line

底線

The biggest concern is that the analysts reduced their earnings per share estimates, suggesting business headwinds could lay ahead for China Zhenhua (Group) Science & Technology. Unfortunately, they also downgraded their revenue estimates, and our data indicates underperformance compared to the wider industry. Even so, earnings per share are more important to the intrinsic value of the business. The consensus price target fell measurably, with the analysts seemingly not reassured by the latest results, leading to a lower estimate of China Zhenhua (Group) Science & Technology's future valuation.

最大的擔憂是,分析師下調了每股收益預期,這表明中國振華(集團)科技可能會面臨業務不利因素。不幸的是,他們還下調了收入預期,我們的數據顯示,與整個行業相比,表現不佳。即便如此,每股收益對業務的內在價值更爲重要。共識目標股價大幅下降,最新業績似乎並未讓分析師放心,這導致對中國振華(集團)科學與技術未來估值的估計降低。

Keeping that in mind, we still think that the longer term trajectory of the business is much more important for investors to consider. We have forecasts for China Zhenhua (Group) Science & Technology going out to 2026, and you can see them free on our platform here.

考慮到這一點,我們仍然認爲該業務的長期發展軌跡對於投資者來說更爲重要。我們對中國振華(集團)科技發展到2026年的預測做出了預測,你可以在我們的平台上免費看到這些預測。

However, before you get too enthused, we've discovered 1 warning sign for China Zhenhua (Group) Science & Technology that you should be aware of.

但是,在你變得太熱情之前,我們已經發現了一個你應該注意的中國振華(集團)科技的警告信號。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

對這篇文章有反饋嗎?對內容感到擔憂嗎?請直接聯繫我們。或者,也可以發送電子郵件至編輯團隊 (at) simplywallst.com。
Simply Wall St的這篇文章本質上是籠統的。我們僅使用公正的方法根據歷史數據和分析師的預測提供評論,我們的文章無意作爲財務建議。它不構成買入或賣出任何股票的建議,也沒有考慮到您的目標或財務狀況。我們的目標是爲您提供由基本數據驅動的長期重點分析。請注意,我們的分析可能不考慮最新的價格敏感型公司公告或定性材料。簡而言之,華爾街沒有持有任何上述股票的頭寸。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論